{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-042630","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.423312+00:00","generated_at":"2026-05-24T10:21:28.311240+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tectonic reports Q4 2024 net loss $12.4M; positive TX45 Phase 1b interim results","bullets":["TX45 Phase 1b Part A reduced PCWP by 17.9% in PH-HFpEF and PVR >30% in CpcPH subgroup.","Completed ~$185.0M private placement in Feb 2025; cash runway into Q4'28.","Cash and equivalents $141.2M at Dec 31, 2024; Q4 net loss $12.4M vs $7.9M year ago.","APEX Phase 2 trial topline results expected in 2026; Phase 1b Part B results expected 2H'25.","TX2100 Phase 1 initiation expected Q4'25 or Q1'26 for hereditary hemorrhagic telangiectasia."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-042630","json":"https://secwatch.observer/filing/0000950170-25-042630.json","markdown":"https://secwatch.observer/filing/0000950170-25-042630.md","text":"https://secwatch.observer/filing/0000950170-25-042630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000095017025042630/0000950170-25-042630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000095017025042630/tecx-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:21:28.311240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}